Table 1.
Baseline characteristics
| Cohort 1: NTRK fusion (n = 29) | Cohort 2: NTRK wild-type (n = 12,456) | ||
|---|---|---|---|
| Non-matched (n = 12,349) | Matched (n = 107) | ||
| Patient characteristics | |||
| Sex, n (%) | |||
| Female | 16 (55.2) | 6785 (54.9) | 62 (57.9) |
| Male | 13 (44.8) | 5563 (45.0) | 45 (42.1) |
| Age, median (range), years | 60 (49–65) | 64 (55–72) | 63 (55–70) |
| Race/ethnicity, n (%) | |||
| Asian | 0 | 291 (2.4) | 1 (0.9) |
| Black/African American | 1 (3.5) | 775 (6.3) | 6 (5.6) |
| Hispanic/Latino | 0 | 36 (0.3) | 0 |
| White/Caucasian | 20 (69.0) | 8379 (67.9) | 76 (71.0) |
| Other | 1 (3.5) | 1106 (9.0) | 9 (8.4) |
| Missing | 7 (24.1) | 1762 (14.3) | 15 (14.0) |
| Primary tumor type, n (%) | |||
| Colorectal cancer | 7 (24.1) | 3927 (31.8) | 28 (26.2) |
| Salivary gland | 5 (17.2) | 82 (0.7) | 12 (11.2) |
| Lung | 4 (13.8) | 4133 (33.5) | 16 (15.0) |
| Sarcoma | 4 (13.8) | 204 (1.7) | 15 (14.0) |
| Pancreatic | 2 (6.9) | 1068 (8.6) | 8 (7.5) |
| Brain medulloblastoma | 1 (3.4) | 22 (0.2) | 4 (3.7) |
| Breast carcinoma | 1 (3.4) | 1313 (10.6) | 4 (3.7) |
| Melanoma | 1 (3.4) | 317 (2.6) | 4 (3.7) |
| Thyroid carcinoma | 1 (3.4) | 48 (0.4) | 4 (3.7) |
| Unknown primary neuroendocrine tumor | 1 (3.4) | 20 (0.2) | 4 (3.7) |
| Unknown primary carcinoma NOS | 1 (3.4) | 394 (3.2) | 4 (3.7) |
| Unknown primary adenocarcinoma | 1 (3.4) | 821 (6.6) | 4 (3.7) |
| ECOG performance status,a n (%) | |||
| 0 | 3 (10.3) | 2074 (16.8) | 12 (11.2) |
| 1 | 2 (6.9) | 2990 (24.2) | 12 (11.2) |
| ≥ 2 | 0 | 1131 (9.2) | 0 |
| Missing | 24 (82.8) | 6154 (49.8) | 83 (77.6) |
| Practice type, n (%) | |||
| Academic | 6 (20.7) | 1346 (10.9) | 21 (19.6) |
| Community | 23 (79.3) | 11,003 (89.1) | 86 (80.4) |
| CGP assay type | |||
| FoundationOne® | 24 (82.8) | 11,754 (95.2) | 94 (87.9) |
| FoundationOne CDx | 1 (3.5) | 492 (4.0) | 3 (2.8) |
| FoundationOne Heme | 4 (13.8) | 210 (1.7) | 10 (9.3) |
| PD-L1 status at CGP report, n (%) | |||
| High (>50) | 0 | 255 (2.1) | 0 |
| Low (1–50) | 2 (6.9) | 287 (2.3) | 1 (0.9) |
| Negative (<1) | 1 (3.5) | 1272 (10.3) | 9 (8.4) |
| Missing | 26 (89.7) | 10,535 (85.3) | 97 (90.7) |
| Serum albumin high vs low,b n (%) | |||
| Serum albumin, g/dL, ≤3.5 | 2 (6.9) | 1839 (14.9) | 5 (4.7) |
| Serum albumin, g/dL, >3.5 | 13 (44.8) | 5860 (47.5) | 48 (44.9) |
| Missing | 14 (48.3) | 4650 (37.7) | 54 (50.5) |
| Serum albumin, g/dL, mean (range) | 4.0 (3.6–4.3) | 3.80 (3.5–4.1) | 4.0 (3.9–4.3) |
| Absolute neutrophil count (109/L),b mean (range) | 5.2 (3.1–7.1) | 4.4 (2.8–6.6) | 4.1 (3.0–5.8) |
| Missing, n (%) | 17 (58.6) | 7490 (60.7) | 68 (63.6) |
| Platelet count (109/L), meanb (range) | 249 (153–301) | 235 (175–309) | 229 (182–285) |
| Missing, n (%) | 16 (55.2) | 4793 (38.8) | 54 (50.5) |
| Clinical management | |||
| Documented antineoplastic use, n (%) | |||
| Yes | 16 (55.2) | 9422 (76.3) | 71 (66.4) |
| No | 13 (44.8) | 2927 (23.7) | 36 (33.6) |
| Antineoplastic on or before CGP report date, n (%) | 12 (41.4) | 7220 (58.5) | 52 (48.6) |
| Documentation of any PD-L1 therapy, n (%) | 1 (3.5) | 1921 (15.6) | 9 (8.4) |
| PD-L1 therapy on or before CGP report date, n (%) | 0 | 643 (5.2) | 2 (1.9) |
| Time from first antineoplastic therapy to CGP report (months), mean (range) | 1.03 (0.31–7.28) | 3.84 (0.07–17.90) | 5.36 (−0.30–26.30) |
| Follow-up time from CGP report (months), mean (range) | 7.49 (2.23–12.50) | 5.72 (1.74–13.50) | 7.56 (2.22–16.20) |
CGP comprehensive genomic profiling, ECOG Eastern Cooperative Oncology Group, NOS not otherwise specified, NTRK neurotrophic tyrosine receptor kinase, PD-L1 programmed death-ligand 1
aLast ECOG performance status reported in 90-day period ending on CGP report date
bLatest measurement within 90 days on or before CGP report date